All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Brentuximab vedotin plus lenalidomide and rituximab for R/R DLBCL: Results from the ELECHON 3 trial

Jul 8, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in diffuse large B-cell lymphoma.

Results from the phase III ELECHON 3 trial (NCT04404283) of brentuximab vedotin (BV) plus lenalidomide(Len) and rituximab (R) vs placebo (Pbo) plus Len and R in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received ≥2 prior lines of systemic therapy were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Jeong.1

Key learnings:

The phase III ELECHON 3 trial met its primary endpoint of overall survival (OS).

The OS was 13.8 months (median follow up [mFU], 15.5 months) vs 8.5 months (mFU, 18.9 months) in the BV+Len+R and Pbo+Len+R arms, respectively (HR, 0.629; 95% confidence interval [CI] 0.445–0.891; p = 0.0085).

BV+Len+R was associated with improved progression-free survival (PFS) and a higher complete response rate vs Pbo+Len+R: mPFS was 4.2 months vs 2.6 months (HR, 0.527; 95% CI, 0.380–0.729; p < 0.0001) and the ORR rates were 64.3% vs 41.5% (p < 0.0006), respectively.

The safety profile of BV+Len+R was consistent with that of the individual agents.

The results from the ELECHON 3 trial suggest that BV+Len+R could be a viable therapeutic option for the treatment of patients with R/R DLBCL, particularly those who cannot receive CAR T-cell therapy or bispecific antibodies or have R/R disease after these treatments.

  1. Kim JA. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Abstract #LBA7005. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 30– Jun 3, 2024; Chicago, US.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox